

ANNUAL REPORT

2022-23

Contents

Welcome from our Chair	3
Who we are	5
About the BLS	6
Our Activities	7
The Scientific Committee	8
The Future	9
Finance and Governance	10



Welcome from Margaret Sneddon

BLS Chair

The past year has been another productive year for the BLS. We have been busier than ever, working hard to ensure we have had a presence at all those conferences and events that offer an opportunity to reach and educate more people who are in a position to recognise and respond to lymphoedema early and to improve the care provide to those with the condition.

While this additional activity makes demands on trustees and Members who support the events, it is a welcome commitment. It suggests there is a growing appetite for knowledge about lymphoedema and guidance to enhance the care provided. Busy clinicians tend to seek out information and education when they become aware of unmet patient needs and recognise there is potential and desire to make a difference to the quality of care provided. It is not so long ago that most healthcare professionals believed that lymphoedema was a rare condition that they were unlikely to encounter and therefore had little need to know much about it. Healthy attendance at the various lymphoedema events, and engagement with the BLS at events addressing wider, related topics seems to indicate not only greater awareness of lymphoedema and how prevalent it is, but also that they have a role to play in the care of people with, or at risk of, lymphoedema.

The BLS considers participation in key events a priority in achieving the Charity's purpose of benefitting those with lymphoedema/chronic oedema in the UK. Events in 2023 have included:

October 2022 – Of course the biggest event of the lymphoedema year for us is the BLS conference. The 2022 event introduced a fresh approach with a number of workshops and a very lively debate that have subsequently driven new workstreams and resource development.

February - National Lymphoedema Conference, now a very successful annual event on which we work in partnership with the Mark Allen Publishing Group and Lipoedema UK to run and for which we develop the annual programme.

March - Wound Care Today, a huge annual 2-day event which enables us to engage with large numbers of community nursing staff, a healthy number of whom register to receive ongoing information from the BLS to extend their knowledge.

March – this was once again Lymphoedema Awareness Week, during which we had a programme of free webinars that were well attended and also viewed many hundreds of times subsequent to the live airing. The topics generated a lot of interest and questions which were followed up on social media or in the quarterly publication 'News & Views'.

May – The Primary Care Show, a huge, busy 3-day event attended by all Members of primary care teams, providing a unique opportunity to engage with general practitioners, physiotherapists, podiatrists and all other disciplines and their various branches.

June - The International Lymphoedema Framework Conference in Nottingham was a rare opportunity to engage with local, national and international delegates, sharing ideas and information with many who visited our exhibition stand and through the programme, to which many of our Members contributed. We were delighted to support the hugely successful full-on event and collaborate in development of the programme. Our Patrons: Professor Mortimer, Professor Keeley, Dr Gordon and several trustees or Members of the BLS Scientific Committee who presented on various topics, all offered rare informal sessions at the BLS stand for questions from delegates.

Concurrent with the ILF conference, we were also involved in Legs Matter Week. There was a new focus this year on highlighting the harm experienced by patients when their lower limb problems are either not recognised, taken seriously or appropriately followed up. The Legs Matter website has been completely revamped in line with this, www.legsmatter.org with a range of new resources and supporting information on what constitutes harm, how it may be avoided and addressed.

Looking ahead to September, we will be both presenting and exhibiting at the Lindsay Leg Club Foundation Conference for the first time, providing yet another opportunity to meet with another different audience.

New resources in development

The BLS are constantly working on initiatives and resource to either raise awareness of lymphoedema, enhance healthcare professional knowledge or support good clinical practice. We were delighted to launch the new Guidance on the Management of Cellulitis in Lymphoedema at the October conference. This joint BLS and Lymphoedema Support Network initiative has become a 'Bible' on the topic across the UK. We have reviewed, revised and updated several existing documents, but have launched fewer new resources.

The main reason for this has been the complexity of the topics we are now addressing some of these, e.g. the BLS Position Document on Manual Lymphatic Drainage has been mooted for many years, but always left in the 'too difficult drawer'. This year we grasped the nettle and brought together a small working group of Members to whom we are extremely grateful for taking up that challenge. A revised clinical guidance document on arterial assessment prior to application of compression for lymphoedema has also been challenging but is now close to completion.

Events, campaigns and resources are the very visible aspects of BLS work. However, there is so much more goes on behind the scenes. We are a learning organisation, not afraid to change, always exploring better, more efficient and cost-effective ways of working. Our Board of Trustees has become diverse and all the stronger as a result. We have worked hard to ensure all our work is underpinned by sound governance, that we are financially secure and have systems and processes in place to ensure a strong future for BLS and continued success in achieving our charitable purposes.

Consequently, we are taking some bold steps over the coming year, planning to initiate work on a new website and ways of managing Membership and our external communications with Members and the general public.

Our achievements and plans as a Society are only possible thanks to the passion, commitment and teamwork of trustees, supported by our contracted staff, faithful Members and Corporate Partners. I extend heartfelt thanks to all who play a part in each of our successes as we strive towards earlier recognition, prompt, appropriate intervention and improved outcomes of treatment. Please continue to support the work of the Charity and together we can make an even bigger difference.

Margaret Sneddon

Chair, British Lymphology Society

Who we are

Chair: Margaret Sneddon (Term 2, Year 2)

Vice Chair: Katie Riches (Term 2, Year 1)

Treasurer: Peter Hooper-Smith (Term 1, Year 1)

Trustees:

- Caitriona O'Neill (Term 2, Year 1)
- Rebecca Elwell (Term 2, Year 2)
- Lorraine Brown (Term 2, Year 3)
- Jane Board (Term 1, Year 3)
- Rachael Hutton (Term 1, Year 3)
- Yolande Borthwick (Term 1, Year 2)
- Jenny Furniss (Term 1, Year 2)
- Fran Campbell (Term 1, Year 1)
- Devina DiCarlo (Term 1, Year 1)
- Tamara Kosevic (Term 1, Year 1)
- Amit Arora (Resigned)
- Debra Alcock (Resigned)

Trustee Vacancies: 0

Co-opted Trustees:

1. Cheryl White (BLS Editor)
2. Rhian Noble-Jones (BLS Scientific Com. Chair from 2020)

Other Key Personnel and Details

Patrons: Professor Peter Mortimer, Trisha Goddard, Professor Vaughan Keeley, Dr Kristiana Gordon

Charity Director: Kate Sinclair, contracted from 1st April 2022 (Project Manager from June 2019)

Administration: Effective Business Management, contracted from 2015, reviewed annually and renewable every two years. Gemini Print Ltd from July 2017 (Printing). ALT Agency from May 2017 (Web design and support). Accountably Ltd from August 2018 (Independent Examiner)

Official Address: British Lymphology Society (from 1st August 2016) P.O. Box 7153, 59 Birmingham Road, Lichfield, WS14 4JW

Banking: Virgin Money PLC, 30 St Vincent Place, Glasgow, G1 2HL and Lloyds Bank PLC, Blackheath, London.

About the BLS

Our Purpose

The preservation and protection of good health among people in the United Kingdom living with lymphoedema/chronic oedema in particular by:

1. Advancing education and knowledge in the field of lymphology and related subjects.
2. Fostering interest in and co-ordinating a strategy for improving the management of chronic oedema, particularly lymphoedema.
3. Producing and maintaining a register of specialist centres in the United Kingdom and Ireland.
4. Improving the knowledge, expertise and skills of health care professionals who treat patients.

Delivering Public Benefit

The Society benefits the public by raising awareness of lymphoedema, how the risk of developing it, or complications arising from it, may be reduced. We develop resources to inform, educate and guide clinical practice. We also seek to use our unique professional leadership position and expertise of our Members to advise government, NHS and other professional bodies and organisations and work with other stakeholders, to raise awareness.

Strategic Priorities

There is much that the Society wishes to achieve. Within the context of the pandemic, we agreed the following priorities for the Charity

1. Increase the profile of lymphoedema
2. Improve accessibility to lymphoedema care
3. Increase reach of the BLS
4. Operational stability

To reach these aims, we have an annual delivery plan, which sets out key projects and work streams to deliver measurable outcomes for the Charity, and those we seek to support.

Our Activities

BLS 2022 Conference

It was a pleasure to return to a face to face conference in 2022 after two years of holding digital conferences. Our Members were glad to be back at our educational event, catching up with old colleagues and networking with our industry partners.

Over 200 delegates and more than 100 exhibitors took part in a new conference format. We opened the conference with a debate on the use of Manual Lymphatic Drainage (MLD) in the treatment of lymphoedema and we welcomed Professor Neil Piller who took part in the debate and gave a presentation. On day one we held a number of workshops where delegates could engage in upcoming projects for the BLS. We are really excited about the outputs of those workshops and it's fantastic to see so many Members taking part in the work of the BLS. The second day was a full day of scientific content, including presentations from invited speakers and many high quality abstract presentations.

We are excited to bring the BLS conference to a new venue in 2023 and look forward to making it even more engaging for our delegates and partners.

Lymphoedema Awareness Week 2023

We had a great start to 2023 with the excitement and run up to the annual Lymphoedema Awareness Week in March. This year, the BLS ran a series of webinars with support from our partners and Members, followed by live Q&A for all those in attendance. We continued with our popular EveryBodyCan campaign and received free publicity and press enquiries thanks to our Patron Trisha Goddard, who had us join her radio show during the week.

We followed a similar format to 2022, but this time increased the promotion across all of our social media accounts. This resulted in hundreds of registrants for the webinars, who subsequently received more information about lymphoedema, becoming a Member and the BLS conference.

Plans are well under way for the 2024 Lymphoedema Awareness Week!

Scientific Committee (BLSSC)

During 2022/23 the Scientific Committee combined online meetings and one face to face meeting to continue to support the BLS Board and its mission, in the following ways:

- Running 5 consecutive workshops of how to write Case Studies at the BLS 2022 conference
- Management of the abstract submission process, anonymous peer review selection process for the 2023 conference. This year attracting 26 submission; 15 of which will become oral presentations and 23 poster presentations.
- Scoring of both the oral and poster presentations at the annual BLS conference
- With the overall aim of promoting research and service development in the field of lymphoedema in the UK

The **Lymphoedema Research Development Grant (LRDG)** has been renamed to reflect a broader range of research development opportunities that it can support. It offers awards of up to £10,000 to BLS Members to develop their skills in research and evidence implementation and further research into lymphoedema in the UK. The new criteria will be announced at conference Oct 2023, widening the scope for applicants to include projects which may not need REC approval but which use research methods (e.g. large service development projects and audits) as long as the outputs are agreed to align with the Charity's objectives.

Scientific Committee Members continue to contribute up to 3 articles for each News & Views newsletter on a range of research and clinical evidence publication topics and have received excellent feedback on the usefulness of these articles.

Clinical Queries - BLSSC Members have regularly provided or signposted to, scientific or clinical advice when are submitted to BLS. The numbers of clinical queries are increasing each year. These are managed anonymously and a generic response is placed in the FAQ section of the BLS website for wider learning.

BLSSC Members also volunteer their time as clinical experts and advisors to bodies such as NICE when **clinical reviews** relevant to Lymphoedema are being conducted or when **national/international guidelines** are being created.

The BLSSC expertise was also sought in this period by other charities such as Macmillan Cancer Support and the Pelvic Radiation Disease Association.

Members of the BLSSC have been part of specific working subgroups of the Board **developing BLS Factsheets** and developing a guidance document on MLD.

There were no vacancies in the current period for the BLSSC but we are encouraged that interest has been shown in the upcoming places.

In relation to **governance**, the BLSSC is subject to the same procedures as the main Board and has been working with the Board to align GDPR and other legal requirements.

Dr Rhian Noble-Jones (BLSSC Chair)
Emma Underwood (BLSSC Vice-chair)

For more information about the BLS Scientific Committee, its Membership and getting involved, see the BLSSC page on the BLS website.

The Future

Lymphoedema Awareness Week begins 6th March 2024

Following the success of the last two year's awareness weeks, we plan to deliver more educational webinars and Q&A sessions online. We are very excited about the educational events already planned, and we will be live on air again with our patron Trisha Goddard.

If you have any plans for Lymphoedema Awareness Week, be sure to let us know so that we can share them with our Members and Friends.

Conference 2024

We are already planning the 2024 conference, building on the successes and lessons of previous years. We'll see more international speakers as well as home-grown talent, and there will be more opportunities for interactive learning and networking.

Big Changes!

Behind the scenes, we are busy working away on bringing you a new website and a refreshed BLS brand. Look out for updates and how you can have your say in these plans.

The Board and management met to make plans for the future, including reviewing the Charity's objects to ensure we remain relevant, and that we are focusing our resources in the right place. Our new branding and values will reflect our aspiration to improve the knowledge understanding and practice of all health care professionals, not only lymphoedema practitioners.

Document Launches

The BLS has been working on some large projects recently, and we will soon be launching the MLD position document, following our popular and engaging debate at conference 2022.

Finance and Governance

Risk Management

Proactive risk identification through regular risk assessments with key stakeholders and project leads means that we systematically map potential risks across the Charity, including financial, operation, regulatory and reputational.

Once risks are identified, we assess their potential impact and likelihood as per the Charity Commission's Risk Management Framework (CC26). This has included strengthening our financial controls, and data and cyber security,

Our risk management procedure includes the methodical reporting of incidents that occur. During the last year, the BLS has experienced two incidents from different external sources. Our process of reporting has also enabled our testing and subsequent amendment of the BLS's investigation form to enhance the description of the event and clarity of the action(s) taken to mitigate risk.

Financial Summary

The BLS has made great progress towards financial stability over the past year. Despite the challenges posed by the pandemic, we have maintained a solid financial position through diligent planning and prudent budget management.

The BLS has added to its reserves in the financial year 2022/3, some of which will be invested in significant projects for the Charity in the coming year.

See Annual Accounts for the full report.



BRITISH LYMPHOLOGY SOCIETY

ANNUAL REPORT TO END OF AUGUST 2023
ANNUAL GENERAL MEETING 7TH NOVEMBER 2023
REGISTERED CHARITY 1185148

Registered charity number: 1185148

Report of the Trustees and
Unaudited Financial Statements
for the year ended 31 March 2023

for British Lymphology Society CIO

British Lymphology Society CIO
Contents of the Financial Statements
for the year ended 31 March 2023

	Page
Information page	1
Report of the Trustees	2
Independent Examiner's Report	3
Statement of Financial Activities	4
Balance Sheet	5
Notes to the Financial Statements	6

**British Lymphology Society CIO
Information Page
for the year ended 31 March 2023**

Registered Charity Number
1185148

Trustees

Chairperson - Margaret Swadden
Vice Chairperson - Katie Radley
Treasurer - Peter Hooper-Smith (appointed 11/05/22)
Treasurer - Dawn Neal (resigned 11/05/22)

Trustees -

Rebecca Elwell
Cathrina O'Spall
Lorraine Brown
Jane Board
Rachel Bottom
Yolande Boethwick
Anny Furniss
Devina Dicufo (appointed 07/09/22)
Tamara Kucovic (appointed 06/11/22)
Euan Campbell (appointed 06/11/22)
Debra Allcock (resigned 01/10/22)
Anni Arora (resigned 01/11/22)
Helen Massey (resigned 01/11/22)

Co-opted Trustee

Cheryl White

BLS Scientific Committee chair

Dr Rhian Nott-Jones

Independent Examiner

J Basileigh BVCA
Accountability Ltd
1st Floor, Unit 12
Compass Point
Froggn Way
Humble
Southampton
Hampshire
SO14 0BA

**British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2023**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity registered with the Charity Commission on 3 September 2019, under registration number 1185148 and is a charitable incorporated organisation (CIO).

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The trustees have assessed the risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to the major risks.

OBJECTIVES AND ACTIVITIES FOR THE PUBLIC BENEFIT

The object of the CIO is the preservation and protection of good health among people in the UK living with lymphoedema/chronic oedema in particular by:

- Advancing education and knowledge in the field of lymphology and related subjects
- Fostering interest in and co-ordinating a strategy for improving the management of chronic oedema, particularly lymphoedema
- Producing and maintaining a register of specialist centres in the UK and Ireland
- Improving the knowledge, expertise and skills of healthcare professionals who treat patients

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities.

ACHIEVEMENTS AND PERFORMANCE

We are pleased to provide an update on the progress and financial stability of the BLS over the past year. Despite the challenges posed by the Covid-19 pandemic, we have maintained a solid financial position through diligent planning and prudent budget management.

Throughout the year, we prioritised the core work of supporting HCPs in treating their patients, and raising awareness of lymphoedema in the UK. We delivered a successful and highly rated Lymphoedema Awareness Week and closely monitored our spending and investment in new systems to help us to grow this campaign year on year.

Our face-to-face Conference returned after two years online, and it exceeded all expectations. We saw remarkable increases in both delegate attendance and sponsorship, and a new format refreshed the learning options for our membership. The event served as a vibrant platform for knowledge exchange, collaboration, and professional development. We extend our gratitude to all partners and members for their support and engagement.

We will continue to adapt to changing circumstances and seize opportunities to make savings so that more of our funds can be invested in the aims of the BLS.

FINANCIAL REVIEW AND RESERVES POLICY

The relevant income, expenditure, cash and receipts for the year are shown under Unrestricted Funds. During the year the charity received income of £219,443, incurred costs of £174,407 resulting in a surplus of £45,036.

As at 31 March 2023 the charity had £405,433 of cash, which includes £22,402 of restricted funds for scientific research. The level of cash held at the year end is higher than expected as it includes £121,601 of sponsorship for the 2023 Conference. The remainder of cash held comprises funds required for updating the charity's website that is planned for in the next financial year and funds required in line with our reserves policy.

The policy of the charity to maintain unrestricted funds which have not been designated for a specific use was extended from six month's expenditure to twelve months' expenditure was approved by the board of trustees on 7 September 2022. The amendment to the policy ensures that reserves at this increased level will be sufficient so that in the event of a significant drop in funding, that the trustees will be able to continue the charity's activities while consideration is given to ways in which additional funds may be raised. The twelve months' expenditure level of reserves was achieved throughout the financial year.

INDEPENDENT EXAMINER

Jonathan Dardagh PCC A has been re-appointed as independent examiner for the coming year.

Approved by order of the board of trustees on 13/09/2023
and signed on its behalf by:


Margaret Goodwin - Chairperson

**British Lymphology Society CIO
Independent Examiner's Report to the Trustees
for the year ended 31 March 2023**

I report to the trustees on my examination of the accounts of the above charity for the year ended 31 March 2023.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts as carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in any material respect:

- 1. the accounting records were not kept in accordance with section 130 the Charities Act; or*
- 2. the accounts did not accord with the accounting records; or*
- 3. the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination*

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



**J Badley FCCA
Independent Examiner**

Accountability Ltd
1st Floor, Unit 12
Compass Point
Ensign Way
Hamble
Southampton
Hampshire
SO11 4RA

18/09/2023

British Lymphology Society CIO
Statement of Financial Activities
for the year ended 31 March 2023

	Notes	Unrestricted fund £	Restricted fund £	2023 Total funds £	2022 Total funds £
INCOMING RESOURCES					
Incoming resources from generated funds					
Voluntary income	2	54,979	-	54,979	38,911
Charitable activities	3	162,967	-	162,967	69,029
Investment income	4	1,159	42	1,201	239
Total incoming resources		219,105	42	219,147	108,180
RESOURCES EXPENDED					
Charitable activities	5	170,796	-	170,796	89,328
Governance costs	6	3,611	-	3,611	5,045
Total resources expended		174,407	-	174,407	94,373
NET INCOMING RESOURCES and net income for the year		44,698	42	45,036	13,787
Net movement in funds		44,698	42	45,036	13,787
RECONCILIATION OF FUNDS					
Total funds brought forward	9	214,772	22,360	236,832	222,849
TOTAL FUNDS CARRIED FORWARD	9	259,470	22,402	281,668	236,637

The Statement of Financial Activities includes all gains and losses in the year and therefore a statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes form part of these financial statements.

British Lymphology Society CIO
Balance Sheet
as at 31 March 2023

		2023 Total funds £	2022 Total funds £
CURRENT ASSETS			
Debtors	7	33,366	75,116
Cash at Bank		415,652	239,826
		<u>449,018</u>	<u>314,942</u>
CREDITORS			
Amounts falling due within one year	8	(106,120)	(98,688)
		<u></u>	<u></u>
NET CURRENT ASSETS		<u>342,898</u>	<u>216,254</u>
NET ASSETS		<u>342,898</u>	<u>216,254</u>
FUNDS			
Unrestricted funds	9	239,246	216,272
Restricted funds		22,862	22,982
		<u>262,108</u>	<u>239,254</u>
TOTAL FUNDS		<u>262,108</u>	<u>239,254</u>

The financial statements were approved by the Board of Trustees on 18 September 2023 and were signed on its behalf by:

M. S. Allen

Chairperson - Margaret Stoddart

P. Harper

Treasurer - Peter Harper-Godwin

The notes form part of these financial statements.

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2023

1 ACCOUNTING POLICIES

(a) *Basis of preparation of the accounts*

The accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to the accounts. The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective January 2019.

(b) *Funds*

General funds represent the funds of the charity that are not subject to any restrictions regarding their use and are available for application for general purposes. Funds designated for a particular purpose by the charity are also unrestricted. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

(c) *Incoming resources*

Donations, legacies and other forms of voluntary income are recognised as incoming resources when receivable, except in so far as they are incapable of financial measurement.

Trading income is shown net of related expenses as this better reflects the contribution of these activities to the charity.

Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of the donation.

(d) *Resources expended*

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity. Governance costs are those associated with the governance arrangements of the charity.

(e) *Taxation*

The charity is exempt from corporation tax on its charitable activities.

2 VOLUNTARY INCOME	Unrestricted funds	Restricted funds	Total funds 2023	Total funds 2022
	£	£	£	£
Membership subscriptions	54,975	-	54,975	38,911
	<u>54,975</u>	<u>-</u>	<u>54,975</u>	<u>38,911</u>

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2023

3 CHARITABLE ACTIVITIES	Unrestricted funds	Restricted funds	Total funds 2023	Total funds 2022
	£	£	£	£
Conference	144,460	-	144,460	61,669
Advertising and other services	18,507	-	18,507	7,360
	<u>162,967</u>	<u>-</u>	<u>162,967</u>	<u>69,029</u>

4 INVESTMENT INCOME	Unrestricted funds	Restricted funds	Total funds 2023	Total funds 2022
	£	£	£	£
Interest receivable	1,459	42	1,501	220
	<u>1,459</u>	<u>42</u>	<u>1,501</u>	<u>220</u>

5 EXPENDITURE - Charitable activities

	Unrestricted funds	Restricted funds	Total funds 2023	Total funds 2022
	£	£	£	£
Professional fees	718	-	718	1,162
Office and administration costs	51,345	-	51,345	59,198
Website, computer and internet costs	3,527	-	3,527	1,318
Newsletters	4,986	-	4,986	2,963
Conference	85,500	-	85,500	947
Promotional items and surveys	3,648	-	3,648	3,470
Wages and expenses	21,072	-	21,072	20,268
	<u>170,796</u>	<u>-</u>	<u>170,796</u>	<u>89,328</u>

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2023

6 EXPENDITURE - Governance costs

	Unrestricted funds	Restricted funds	Total funds 2023	Total funds 2022
	£	£	£	£
Book-keeping	916	-	916	2,232
Independent examiner	1,650	-	1,650	1,800
Insurance	883	-	883	790
Committee meetings	162	-	162	223
	<u>3,611</u>	<u>-</u>	<u>3,611</u>	<u>5,045</u>

7 DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Trade debtors	4,096	70,461
Other debtors	28,268	4,593
	<u>32,364</u>	<u>75,054</u>

8 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Trade creditors	7,604	11,248
Deferred income	145,118	83,710
Accrued charges	5,407	3,490
	<u>158,129</u>	<u>98,448</u>

9 MOVEMENT ON UNRESTRICTED AND RESTRICTED FUNDS

	Balance at 1 April 2022	Incoming resources	Outgoing resources	Transfers between funds	Balance at 31 March 2023
	£	£	£	£	£
Unrestricted					
General fund	214,272	219,491	(174,407)	-	219,356
Restricted fund:					
Scientific research	22,360	42	-	-	22,402
	<u>236,632</u>	<u>219,533</u>	<u>(174,407)</u>	<u>-</u>	<u>281,668</u>

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2023

10 ANALYSIS OF NET ASSETS BETWEEN FUNDS	Tangible fixed assets £	Net current assets £	Total £
Unrestricted: General fund	-	259,266	259,266
Restricted: Scientific research	-	22,402	22,402
	-	281,668	281,668

11 OTHER BENEFITS RECEIVED BY THE CHARITY

We are grateful to our corporate members for their generosity and their support in the 2022 conference. In addition, thank you to all who sponsor us in formal and informal ways.

12 TRUSTEES REMUNERATION AND EXPENSES

The following trustees received reimbursement of expenses during the year:

	£
K. Richey	92.00
M. Sneddon	455.00
R. Noble-Jones	216.00
C. O'Neill	109.00
R. Elwell	185.00
L. Brown	245.00
J. Board	375.00
C. White	1,837.00
Y. Borthwick	60.00
P. Hooper-Smith	968.00
F. Campbell	176.00

No trustee nor anyone connected with them received any remuneration during the period in respect of their services as trustees.

British Lymphology Society CIO
Independent Examiner's Report to the Trustees
for the year ended 31 March 2023

I report to the trustees on my examination of the accounts of the above charity for the year ended 31 March 2023.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts as carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in any material respect:

1. the accounting records were not kept in accordance with section 130 the Charities Act; or
2. the accounts did not accord with the accounting records; or
3. the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



J Badley FCCA
Independent Examiner

Accountability Ltd
1st Floor, Unit 12
Compass Point
Ensign Way
Hamble
Southampton
Hampshire
SO11 4RA

18/09/2023